17 results on '"Puduvalli, Vinay K."'
Search Results
2. Early imaging marker of progressing glioblastoma: a window of opportunity
3. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
4. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms
5. Impact of provider level, training and gender on the utilization of palliative care and hospice in neuro-oncology: a North-American survey
6. Inhibition of Angiogenesis as a Therapeutic Strategy against Brain Tumors
7. A multi-resolution textural approach to diagnostic neuropathology reporting
8. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
9. Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma
10. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study
11. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures
12. Progressive multifocal leukoencephalopathy in a patient with glioblastoma
13. Papillary endothelial hyperplasia presenting as recurrent malignant glioma
14. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma
15. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma
16. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
17. Chemotherapy as first line treatment for oligodendroglioma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.